Acquisition of Medications for skin conditions, under framework agreement 2023/490, for the year 2026

This tender concerns the acquisition of medications specifically used for treating skin conditions. The procurement is being conducted under the framework agreement 2023/490 and is intended to cover the supply needs for the year 2026. The objective is to secure a reliable source of dermatological medications to meet the healthcare requirements of the organization or its beneficiaries. The scope will involve specifying the exact list of medications, their required dosages, quantities, and quality standards, likely adhering to pharmaceutical regulations and pharmacopoeia standards. The framework agreement mechanism suggests that pre-qualified suppliers have already been identified, and this tender likely focuses on placing specific orders or establishing call-off contracts for the upcoming year. The selected supplier(s) will be responsible for the timely delivery of these essential medicines, ensuring proper storage and handling conditions. This procurement is critical for providing necessary medical treatment for skin ailments, contributing to public health and patient well-being. Emphasis will likely be placed on the quality, efficacy, and cost-effectiveness of the supplied pharmaceuticals.

This is a supplies contract in the health and medical services, trade and industry and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 2,282.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.